The endotoxin-lipoprotein hypothesis

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: west of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S), Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453 Vredevoe, 1998, Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy, Am J Cardiol, 82, 323, 10.1016/S0002-9149(98)00334-8 Richartz, 1998, Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system, Cardiology, 89, 184, 10.1159/000006785 Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1 Maron, 2000, Current perspectives on statins, Circulation, 101, 207, 10.1161/01.CIR.101.2.207 Vaughan, 1996, Statins do more than just lower cholesterol, Lancet, 348, 1079, 10.1016/S0140-6736(96)05190-2 Kronmal, 1993, Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data, Arch Intern Med, 153, 1065, 10.1001/archinte.1993.00410090025004 Forette, 1989, Cholesterol as risk factor for mortality in elderly women, Lancet, i, 868, 10.1016/S0140-6736(89)92865-1 Jacobs, 1992, Report of the Conference on Low Blood Cholesterol: mortality associations, Circulation, 86, 1046, 10.1161/01.CIR.86.3.1046 Flegel, 1993, Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-I, Infect Immun, 61, 5140, 10.1128/IAI.61.12.5140-5146.1993 Harris, 1990, Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice, J Clin Invest, 86, 696, 10.1172/JCI114765 Levine, 1993, In vivo protection against endotoxin by plasma high density lipoprotein, Proc Natl Acad Sci USA, 90, 12040, 10.1073/pnas.90.24.12040 Netea, 1998, Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells, Infect Immun, 66, 2365, 10.1128/IAI.66.5.2365-2367.1998 Read, 1995, Triglyceride-rich lipoproteins prevent septic death in rats, J Exp Med, 182, 267, 10.1084/jem.182.1.267 Wurfel, 1994, Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS, J Exp Med, 180, 1025, 10.1084/jem.180.3.1025 Hubsch, 1995, Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models, J Lab Clin Med, 126, 548 Feingold, 1995, Role for circulating lipoproteins in protection from endotoxin toxicity, Infect Immun, 63, 2041, 10.1128/IAI.63.5.2041-2046.1995 Netea, 1996, Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections, J Clin Invest, 97, 1366, 10.1172/JCI118556 Schumann, 1990, Structure and function of lipopolysaccharide binding protein, Science, 249, 1429, 10.1126/science.2402637 Beutler, 2000, Tlr4: central component of the sole mammalian LPS sensor, Curr Opin Immunol, 12, 20, 10.1016/S0952-7915(99)00046-1 Wagner, 1998, Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha, Circ Res, 82, 47, 10.1161/01.RES.82.1.47 Frantz, 1999, Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium, J Gin Invest, 104, 271, 10.1172/JCI6709 Boren, 1998, Apo BlOO-containing lipoproteins are secreted by the heart, J Clin Invest, 101, 1197, 10.1172/JCI1785 Niebauer, 1999, Endotoxin and immune activation in chronic heart failure: a prospective cohort study, Lancet, 353, 1838, 10.1016/S0140-6736(98)09286-1 Segal, 2000, (on behalf of the ELITE II). Effects of HMG-COA reductase inhibitors (statins) in patients with heart failure, Europ J Heart Fail, 2, 96, 10.1016/S1388-9842(00)80342-6 Vonhof, 1998, Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy, Int J Cardiol, 63, 237, 10.1016/S0167-5273(97)00332-X Matsumori, 1994, Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure, Circulation, 89, 955, 10.1161/01.CIR.89.3.955 Shimokawa, 1998, Cytokine generation capacities of monocytes are reduced in patients with severe heart failure, Am Heart J, 136, 991, 10.1016/S0002-8703(98)70155-3 Lequier, 2000, Preoperative and postoperative endotoxaemia in children with congenital heart disease, Chest, 117, 1706, 10.1378/chest.117.6.1706 Gordon, 1996, Low-lipid concentrations in critical illness implications for preventing and treating endotoxemia, Crit Care Med, 24, 584, 10.1097/00003246-199604000-00006